A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC).

Trial Profile

A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2012

At a glance

  • Drugs Docetaxel; Panobinostat; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 25 Aug 2009 Actual patient number (16) and actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top